Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Acta Neurologica Belgica
Published in: Acta Neurologica Belgica 2/2022

01-04-2022 | Migraine | Original article

Indomethacin for refractory COVID or post-COVID headache: a retrospective study

Authors: Abouch V. Krymchantowski, Raimundo Pereira Silva-Néto, Carla Jevoux, Ana Gabriela Krymchantowski

Published in: Acta Neurologica Belgica | Issue 2/2022

Login to get access

Abstract

Background

COVID-19, a disease caused by SARS-CoV-2, manifests with headache, both in the acute phase and as a post-infection symptom, which may be refractory to usual analgesics.

Objectives

Investigate the therapeutic response of refractory COVID or post-COVID headache to indomethacin.

Methods

This was an observational, retrospective, open and uncontrolled. A sample of 37 patients diagnosed with COVID-19 presenting headache during the acute phase or after the resolution of the disease, with refractoriness to the usual symptomatic medication was treated with indomethacin.

Results

Of the 37 patients (24 women and 13 men), 29 were migraineurs and 8 had no previous history of headache. The average age was 40.4 ± 9.4 years, ranging from 19 to 65 years. In 26 (70.3%) patients, the onset of headache occurred within 72 h, and in 11 (29.7%), after 10 days of positivity for Sars-CoV-2. After treatment with indomethacin, 36 patients reported greater than 50% headache relief from the third day and 5 became asymptomatic on the fifth day.

Conclusions

In patients with migraine or no prior history of headache who present with refractory COVID or post-COVID headache to common analgesics, anti-inflammatory drugs, and/or triptans, indomethacin should be considered a therapeutic option.
Literature
1.
Shehata GA, Lord KC, Grudzinski MC, Elsayed M, Abdelnaby R, Elshabrawy HA (2021) Neurological complications of COVID-19: underlying mechanisms and management. Int J Mol Sci 22(8):4081CrossRef
2.
Vehar S, Boushra M, Ntiamoah P, Biehl M (2021) Post-acute sequelae of SARS-CoV-2 infection: caring for the ‘long-haulers.’ Cleve Clin J Med 88:267–272CrossRef
3.
Lechien JR, Chiesa-Estomba CM, De Siati DR, Horoi M, Le Bom SD, Rodriguez A et al (2020) Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Otorhinolaryngol 277(8):2251–2261CrossRef
4.
Kim ES, Chin BS, Kang CK, Kim NJ, Kang YM, Choi JP et al (2020) Clinical course and outcomes of patients with severe acute respiratory syndrome coronavirus 2 infection: a preliminary report of the first 28 patients from the Korean cohort study on COVID-19. J Korean Med Sci 35(13):e142CrossRef
5.
Liang WH, Guan WJ, Li CC, Li YM, Liang HR, Zhao Y et al (2020) Clinical characteristics and outcomes of hospitalized patients with COVID-19 treated in Hubei (epicentre) and outside Hubei (non-epicentre): a nationwide analysis of China. Eur Respir J 55(6):2000562CrossRef
6.
Machado FC, Carone Neto G (2021) Carone RSD (2021) Sphenopalatine ganglion block for refractory COVID-19 headache: a descriptive case series. Braz J Anesthesiol S0104–0014(21):00189–00195
7.
8.
Summ O, Andreou AP, Akerman S, Holland PR, Hoffmann J, Goadsby PJ (2021) Differential actions of indomethacin: clinical relevance in headache. Pain 162(2):591–599CrossRef
9.
Akerman S, Karsan N, Bose P, Hoffmann JR, Holland PR, Romero-Reyes M et al (2019) Nitroglycerine triggers triptan-responsive cranial allodynia and trigeminal neuronal hypersensitivity. Brain 142(1):103–119CrossRef
10.
Iversen HK, Olesen J (1994) Nitroglycerin-induced headache is not dependent on histamine release: support for a direct nociceptive action of nitric oxide. Cephalalgia 14(6):437–442CrossRef
11.
Akerman S, Williamson DJ, Kaube H, Goadsby PJ (2002) The effect of antimigraine compounds on nitric oxide-induced dilation of dural meningeal vessels. Eur J Pharmacol 452(2):223–228CrossRef
12.
Summ O, Andreou AP, Akerman S, Goadsby PJ (2010) A potential nitrergic mechanism of action for indomethacin, but not of other COX inhibitors—relevance to indomethacin-sensitive headaches. J Headache Pain 11(6):477–483CrossRef
13.
Gonzalez-Martinez A, Planchuelo-Gómez Á, Guerrero ÁL, García-Azorín D, Santos-Lasaosa S, Navarro-Pérez MP et al (2021) Evaluation of the impact of the COVID-19 lockdown in the clinical course of migraine. Pain Med 28:449
14.
Gentile E, Delussi M, Abagnale C, Caponnetto V, De Cesaris F, Frattale I et al (2021) Migraine during COVID-19: data from second wave pandemic in an Italian cohort. Brain Sci 11(4):482CrossRef
15.
Uygun Ö, Ertaş M, Ekizoğlu E, Bolay H, Özge A, Kocasoy Orhan E et al (2020) Headache characteristics in COVID-19 pandemic – a survey study. J Headache Pain 21(1):121CrossRef
16.
Al-Hashel JY, Ismail II (2020) Impact of coronavirus disease 2019 (COVID-19) pandemic on patients with migraine: a web-based survey study. J Headache Pain 21(1):115CrossRef
17.
Headache Classification Subcommittee of the International Headache Society (2018) The international classification of headache disorders, 3rd edition. Cephalalgia 38:1–211
18.
Harapan H, Michie A, Sasmono RT, Imrie A (2020) Dengue: a minireview. Viruses 12(8):829CrossRef
19.
Harapan H, Michie A, Mudatsir M, Nusa R, Yohan B, Wagner AL et al (2019) Chikungunya virus infection in Indonesia: a systematic review and evolutionary analysis. BMC Infect Dis 19(1):243CrossRef
20.
Mutiawati E, Syahrul S, Fahriani M, Fajar JK, Mamada SS, Maliga HA et al (2021) Global prevalence and pathogenesis of headache in COVID-19: a systematic review and meta-analysis. F1000Research 9:1316CrossRef
21.
Zayet S, Kadiane-Oussou NJ, Lepiller Q, Zahra H, Royer PY, Toko L et al (2020) Clinical features of COVID-19 and influenza: a comparative study on Nord Franche-Comte cluster. Microbes Infect 22(9):481–488CrossRef
22.
Vacchiano V, Riguzzi P, Volpi L, Tappatà M, Avoni P, Rizzo G et al (2020) Early neurological manifestations of hospitalized COVID-19 patients. Neurol Sci 41(8):2029–2031CrossRef
23.
Tian S, Chang Z, Wang Y, Wu M, Zhang W, Zhou G et al (2020) Clinical characteristics and reasons for differences in duration from symptom onset to release from quarantine among patients with COVID-19 in Liaocheng. China Front Med (Lausanne) 7:210
24.
Huang R, Zhu L, Xue L, Liu L, Yan X, Wang J et al (2020) Clinical findings of patients with coronavirus disease 2019 in Jiangsu province, China: a retrospective, multi-center study. PLoS Negl Trop Dis 14(5):e0008280CrossRef
25.
Bolay H, Gül A, Baykan B (2020) COVID-19 is a real headache! Headache 60(7):1415–1421CrossRef
26.
Ong JJY, Bharatendu C, Goh Y, Tang JZY, Sooi KWX, Tan YL et al (2020) Headaches associated with personal protective equipment - a cross-sectional study among frontline healthcare workers during COVID-19. Headache 60(5):864–877CrossRef
27.
28.
29.
Alkotaji M, Al-Zidan RN (2021) Indomethacin: can it counteract bradykinin effects in COVID-19 patients? Curr Pharmacol Rep 22:1–5
30.
31.
Ho P, Zheng J-Q, Wu C-C, Hou YC, Liu WC, Lu C-L et al (2021) Perspective adjunctive therapies for COVID-19: beyond antiviral therapy. Int J Med Sci 18:314–324CrossRef
32.
Amici C, Di Caro A, Ciucci A, Chiappa L, Castilletti C, Martella V et al (2006) Indomethacin has a potent antiviral activity against SARS coronavirus. Antivir Ther 11(8):1021–1030PubMed
Metadata
Title
Indomethacin for refractory COVID or post-COVID headache: a retrospective study
Authors
Abouch V. Krymchantowski
Raimundo Pereira Silva-Néto
Carla Jevoux
Ana Gabriela Krymchantowski
Publication date
01-04-2022
Publisher
Springer International Publishing
Published in
Acta Neurologica Belgica / Issue 2/2022
Print ISSN: 0300-9009
Electronic ISSN: 2240-2993
DOI
https://doi.org/10.1007/s13760-021-01790-3

Other articles of this Issue 2/2022

Acta Neurologica Belgica 2/2022 Go to the issue

Review article

Pharmacological neuroprotection and clinical trials of novel therapies for neonatal peri-intraventricular hemorrhage: a comprehensive review

Letter to the Editor

COVID-19-booster vaccine-induced encephalitis

Letter to the Editor

MOG antibody-associated disease presenting with tumefactive lesions and closed-ring enhancement

Original article

Incidence of acute ischemic cerebrovascular events in a cohort of HIV-infected patients

Original article

Predictive value of metabolic and perfusion changes outside the seizure onset zone for postoperative outcome in patients with refractory focal epilepsy

Letter to the Editor

Functional tremor in Wilson’s disease